Incyte Corporation
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersWilmington, DE
US patents663
SAM.gov UEIZTM9U2G5VTK8
CAGE code1F8A9
Incorporated inDE
LEI549300Z4WN6JVZ3T4680
- unmet medical needs
- therapeutic areas
- inflammation
Named on the company’s own website, read JUL 29, 2026
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
663 US patents granted 2003–2025, 265 of them in the five years to SEP 2025.
Pharmaceuticals 456Organic fine chemistry 172Measurement 17Biotechnology 17Furniture, games 1
- Process and intermediates for preparing a JAK1 inhibitorUS 12,428,426 · granted SEP 30, 2025
- Tricyclic heterocycles as FGFR inhibitorsUS 12,428,420 · granted SEP 30, 2025
- Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the sameUS 12,427,154 · granted SEP 30, 2025
- Aminopyrazine derivatives as PI3K-γ inhibitorsUS 12,421,197 · granted SEP 23, 2025
- Pyrrolotriazine compounds as tam inhibitorsUS 12,415,809 · granted SEP 16, 2025
Newest 5 shown · Granted to Incyte Corporation · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Incyte Corporation | Wilmington | DE | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.